You are here: Home » Current Affairs » News » National
Business Standard

AI to help find which patients will respond to cancer therapy: Study

The study, published in the journal Cancer Immunology Research, noted that the AI system can assess the scans taken when lung cancer is first diagnosed in a patient

Topics
Artificial Intelligence in health | artifical intelligence | cancer treatment

Press Trust of India  |  Washington 

technology, artificial intelligence
Representative Image

Researchers have developed a novel artificial intelligence (AI) based method to determine which lung-cancer patients may benefit from an expensive treatment called immunotherapy, an advance that may help reduce health care costs for underprivileged cancer patients.

The study, published in the journal Cancer Immunology Research, noted that the AI system can assess the scans taken when lung cancer is first diagnosed in a patient, and compare it to scans taken after the first 2-3 cycles of treatment to find changes.

The researchers, including those from the Case Western Reserve University in the US, used an X-ray imaging equipment called a CT scan to probe into tissue samples from 50 patients.

Using these scans, they trained the AI system to create an algorithm for identifying changes in the lung-cancer lesion.

The researchers said currently only about 20 per cent of all cancer patients benefit from immunotherapy -- which is a treatment that uses drugs to help one's own immune system to fight cancer, as opposed to chemotherapy drugs which directly target and kill cancer cells.

"Even though immunotherapy has changed the entire ecosystem of cancer, it also remains extremely expensive--about $200,000 per patient, per year," said study co-author Anant Madabhushi from the Case Western Reserve University.

"That's part of the financial toxicity that comes along with cancer and results in about 42 per cent of all new diagnosed cancer patients losing their life savings within a year of diagnosis," he added.

Madabhushi said the new tool can do a better job of matching up which patients will respond to immunotherapy, "instead of throwing $800,000 down the drain".

According to the researchers, one of the significant advances in the research was the AI tool's ability to spot the changes in texture, volume and shape of a cancer lesion, not just its size -- which they said is often the only parameter used by doctors to identify cancerous growths.

The scientists said the results were consistent across scans of patients treated at two different sites, and with three different types of immunotherapy drugs.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, November 23 2019. 18:51 IST
RECOMMENDED FOR YOU
.